MIRA
INFORM REPORT
|
Report Date : |
14.05.2007 |
IDENTIFICATION DETAILS
|
Name : |
DYSON RESEARCH LABORATORIES (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
59-U, Aibak Block, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
2003 |
|
|
|
|
Com. Reg. No.: |
00000012456/20030102 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Business Name
DYSON RESEARCH LABORATORIES (PRIVATE) LIMITED
Full Address
|
Registered Address |
|
59-U, Aibak Block, |
|
Tel |
92 (42) 5830217, 5847858 |
|
Fax |
92 (42) 5752339 |
|
Website |
Short Description Of
Business
|
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
Year Established |
2003 |
|
Registration # |
00000012456/20030102 |
Branches
|
Address |
|
|
Tel # |
92 (42) 2401287, 2401295 |
|
Fax # |
92 (42) 2401296 |
Front
Office (
2442,
Factory Location
28 K.M.,
Auditors
M/s Javaid Jalal Amjad & Co.
(Chartered
Accountants)
Legal Status
Subject Company was established as a Private Limited Company in 2003
|
Authorised Capital |
Rs. 10,000,000/- |
|
Issued & Paid up Capital |
Rs. 9,910,040/- |
Details of Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Dr. Zafar Mustafa
Jajjah Dr. Tahir Sharif Mr. Mubashar Javed Mr. Jehanzeb Rauf
Kahlon |
Pakistani Pakistani Pakistani Pakistani |
House # 74, Block-D, Gulberg III, Lahore 59-U, Aibak Block, E-31/1, 59-U, Aibak Block, |
Business Business Business Business |
Chief Executive Director Director Director |
Shareholders
|
Names of Shareholders |
|
Dr. Zafar Mustafa Jajjah Dr. Tahir Sharif Mr. Jehanzeb Rauf Kahlon Mr. Haji Mahmood Ahmad Virk Mr. Faisal Mustafa Jajjah Mr. Iqbal Ahmad Choudhry Mr. Javaria Khalid Mr. Siddique Ahmad Mrs. Tahira Khatoon Mr. Mubashar Javed |
Associates
Subsidiary
None
Associated Companies
(1) God Bless
International (Private) Limited,
Products
Manufacture & Marketing of Pharmaceutical Products
including Anti Anemic, Anti Depressant, Anti Epileptic, Anti Histamine, Anti
Malarial, Anti Rheumatic, Anti Ulcerant, Antibiotic, Cough Supressant, NSAID by
their brand name of WINPRAM, GLOREX,
DYTADINE, VASOFAX, XYDENE, DANKE, TALGESIC, NABKAST, PURPAL, TOPRAZOL, BEMOX,
GETWEL, LEVOSON, PULMOX-DM, PULMOX-E, NAPRICAL, NIMCOX
Number of Employees
104
Annual Production
Volume
The capacity and production of the company’s plant is
indeterminable as it is multi-product and involves varying processes of
manufacture
Annual Sales Volume
|
Year |
In Pak Rupees |
|
2005 - 2006 |
60,000,000/- (Estimated) |
Importing Countries
Import of Pharmaceutical Raw Materials from Europe,
Distributors
Subject authorized distributors currently exist in all major
cities of
Exporting Countries
Mainly to
Bankers
The Bank of
(Mortgage obtained PKR
60,542,000/-)
Habib Bank Limited,
Standard Chartered
Soneri Bank Limited,
Memberships
Foreign Exchange
Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 60.60 |
|
UK Pound |
1 |
Rs. 119.70 |
|
Euro |
1 |
Rs. 81.65 |
Comments
Subject Company was incorporated in 2003 and is engaged in
manufacture & marketing of Pharmaceutical Products.
Market reputation is good. Trade relations are reported as fair. The
Company can be considered for normal business dealings at usual trade terms and
conditions.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)